TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact 中文

Press Release

16

Jan, 2020

Transcenta Attends 38th Annual J.P. Morgan Healthcare Conference, CEO Dr. Xueming Qian Delivers Speech and Shares Progress

Transcenta Holding’s Chief Executive Officer Dr. Xueming Qian delivered a speech at the 38th Annual J.P. Morgan Healthcare Conference held in San Francisco, US yesterday. He shared with hundreds of invited guests and investors across the world Transcenta’s progress on key assets in the pipeline and the company’s future plans.

08

Jan, 2020

Transcenta Holding Secures $100 Million Series B Plus Financing

Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, R&D, and manufacturing of antibody-based therapeutics, announces today that it has sealed a 100 million USD series B+ round. CR-CP Life Science Fund ("CR-CP") and Fortune Capital co-led the financing round, participated by new investors including Epiphron Capital, CCT China Merchant Buyout Fund, China Equity Group, as well as the existing shareholders including Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners, Sequoia Capital China, and ARCH Venture Partners. China Renaissance acted as the exclusive financial advisor for this transaction.

17

Jul, 2019

Transcenta Announces IND Approval for Third-generation Death Receptor 5 Agonist to Conduct Clinical Trials in China

Transcenta Holding, a global biotherapeutics company with fully integrated capabilities in the research, development, regulatory affairs and manufacturing of biologics, today announced that its Death Receptor 5 (DR5) Agonist, an innovative antibody internally named as JCT205, has been cleared by the Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) to conduct phase I clinical trial in China.

29

Mar, 2019

Transcenta Holding Announces Licensing Agreement with Lilly

Transcenta Holding (Transcenta) today announces that its wholly-owned subsidiary, HJB, has signed an exclusive agreement with Eli Lilly and Company (Lilly) to license a portfolio of novel biotherapeutics programs in the therapeutic area of bone diseases for development and commercialization in Greater China, including the phase 2-completed Blosozumab, a humanized antibody to sclerostin. Transcenta will be responsible for the overall preclinical/clinical development, regulatory filing and manufacture of these biologic therapeutics. As part of this transaction, Lilly will receive an upfront payment in cash plus equity shares in Transcenta, and will be eligible for potential regulatory and sales milestones, and commercial royalty payments.

11

Mar, 2019

Transcenta Holding announces appointment of Dr. Yi Gu as Senior Vice President and Head of Research

Transcenta Holding (Transcenta), an innovative biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing, announced today the appointment of Dr. Yi Gu as its Senior Vice President and Head of Research.

02

Jan, 2019

MabSpace Biosciences Merged with HJB to Form Transcenta Holding, a Fully Integrated Leading Global Biotherapeutics Company

HJB and MabSpace Biosciences (MabSpace) today announced that the two companies have entered into a definitive merger agreement to create Transcenta Holding Ltd., (Transcenta), a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics. Dr. Xueming Qian, former Founder, Chairman and CEO of MabSpace, will serve as chief executive officer while Dr. Jonathan Yining Zhao, Co-founder and CEO of HJB, will be the Executive Chairman of the combined company, respectively.

1 2 3 4 5